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11 o e:1oYi Thmml~Wtolxmie n• La~e, tnterniltiomll Trkd 
" " of the OP IIb/ll~ Ifthibltor F.~tiflbetlde in I~tkmts 
With A©uto Corene~ry Syndromes 
M, McCIur~, N,~, Kl~im~n, LG, I~i~rd~n, R Spar'dtpani, E,J, T_~9!, R, D_i~,~. 
RM, Ca!lff, ID. GrCU@r, KR  Kar~h, RA, H aeTit~Jt0~, FOr ~ PUR-~U!T 
tnve, f~ti~to.'~; 13~k~ Clm¢#l Re,:~a¢h Institute, C~rham, NC, USA 
~;k~Otmd: Ptatalgt (pll) inl~ibition vi~ GP IIl~ll!a r~Pt0r b l0¢k~ =S as. 
sociatecJ with ~ low I~jt pot~nti=ally ~npa~z]nt lnctd~nce of thr0mbocytopon=a 
(T)~ We sought to exel~tine th~ i ~  O! T in PURSUIT, a mutticenter 
intem~ lionel cliniC.~l thpl 5tuclying this rn~de of ptatelet inhlb~tl0n. 
Methe.~: 10,948 p a.tients with a~ non.ST elcveltion acule c=anap/syn. 
dr0me for <24 ho_g~ va~e ~ e c l  to treatment with eptifdpatide, a
platalet GP Itb/llla receptor antagortist, or ~bo  for up to 96 hours. Pa- 
tients received asl~rin and hepmin. T was defim~l as acute (pit <50% Of 
baseline or <100,000/ram3), se~mm (pit <50,Q00 mrr,3), or profound (pit 
< 20,QO0~mm :~). 
Results: 
O~e rail (n = 10.IB49) Eptdzbahde tn = 4.679) PreceDe (n - 4.696) 
ACUte T 6 9% 6 B% 6 7% 
Sea, ere T 05% 06% 04% 
Profound e 1% 02% 0 6% 
Concluszon: T Occurs infrequently but not rarely arp~ng patients v,~th 
non-ST elevation acute COronary syndromes. The overaJl in.dance of T 
was similar between treatment groups, with a slight excess of severe and 
profound T associated with eptifil~tide. The clinical signififance of T in this 
pOpular=on remoras to be deterr~ned. 
1028-108]  Prior Aspirin use Potentiates the of Efhmt GP 
IIbJIIla Inhibition in Patients With Non-ST 
Elevation Acute Coronary Syndromes 
JH. Alexander, R.A. Hardngton, A. Guerci, B.D. Weathedey. K.R Karsch. 
R,M. Califf, E.J, Topoi, A.M. Linceff, P.W. Armstrong. F~rthe PURSUIT 
Investigators: Duke Cl:ncal Research Insbtute. Durham. NC, USA 
BaCkgrOund: ASpirin (ASA) is the moss commonly used anti-platetet agent in 
pts with coronary artery disease. The additional benefit of GP lib/Ills inhibition 
during an acute coronary event in pts already on ASA iS unknown. 
MethOds: The PURSUIT tnal randomized 10,948 pts with non-ST eleva- 
tion acute coronary syndromes to bolus and infusion of eptitibatide or placabc 
for up to 72 hours. Pts were followed for 3Od death or non-fatal MI. Protocol 
ASA use (160 mg then 75.-~325 rapid) was recommended in all Lots, We stud- 
ied the relationship between poor ASA use (within 2 weeks) and treatment 
effect of eptitibalide. 
Results: Overall, prior ASA use was 63.6% and did not vary across 
treatment arms. Death or MI by ASA use and treatment is diSplayed: 
Placebo Epfdibatide RR 95% CI 
No prior aspirin 12 9% 13 1% 102 (0.84, 1.25) 
Prior aspinn" 173% 149% 084 (0.73, 0.96) 
Conclusions: Pts with prior ASA use derived particular benefit from GP 
lib/Ilia inhibition. While this counters the expectation that them would be 
less potential therapeutic effect in patients with prior antiplatelet use, the 
mechanism of ASA resistance may be explanatory and deserves further 
study. 
. . . . . . . . . .  Plotolot AggmgMIon RHponss Of EptlfllN#lde 
.A.d~inl.MeyOdlntmvonouMy in Poti~lto With 
unstable Angina or Non-Q;Waw ~ L M  
InfnP~'~en 
L J¢nnin~,, E, Tardiff, O, Phillips, R, Scarborough, M, Kilt, O, Gral~f, 
Unlv~r~ty at7~, M~;mp~. 'rN; ~e  UnivaC, {~a,~n, NC: COR 
B~(~-(,Jr..e; Eptifit~ttd0 i~ ~ pint,let tit~nne~n tm:.eplor emt~l~t  eu~tat~ 
for IV edmin~tratior), PERIGEE is ~ ~ul~igo'y 0f PURSUIT, # m~ltic~ntar, 
r~n~mized placer]o-controlled tr~l in p~tienta with unsWplo l~ngin,~ or SuS, 
p~t~t MI without ST 5egm0nl L~ov~tiori, 
M~tho~; A pll~c,~t~o group an~ e tr~tm~nt regimen at a 180 ~g)kg 10ol~s 
follOWed by el 2,0 Hg/kgJmin infus0on rate Up to 7~ hr were inve~gat_ed, An 
o_bjective wets to determine= the ¢'0n~_nlration.r~pert~ Cu~ ~t ~plitiiP~tida 
~,  pli~00 for ex viva platolet el00r0gatton (PA) ~ plata~t GPllb-411a 
receptor occupancy (RO) The extent RO w_as dotermi~ I~y the. I~ndin 0
of the_ I~ m,~ wHIch meaiiures the I;~rfant of total GPllb-~tIlel re~pptors 
With Pound drug, Both PA en~ RO were famed out I;~om e~tifil0ati(3~ w~ 
administered, m timepomt~ after dm 0 initiation, plier to drug disr, Onl~nL~tion, 
and at 4 hr and 8 hr after di=¢,onfinuation, 
Re, u/is: More than 80% et palmate achmved 80% inhtl~tion of PA to 20 
~M ADP immod~taly after the IV ~mlus ~ under staa~/$5tlto conditian~, 
Platelet inh;bitmn was rap~dty reverses with PA returning to I~lselifle within 
4-8 hr after discontinuation o! infusion, The RO results temporaJly parai!eled 
the profile ol inhibition of PA. 45% of the patients ~hieved 80% RO after 
the IV bolus and more than 65% ach i~ ~ Re under Ste,L~y state 
conditions. A Re ol less than 60% was measured at 8 hr after discontinuation 
of infuszon. Furthermore, PK data proved a strong relationship between 
epbrubat~le plasma Car, contralto,s and Re. 
Conc/uszons: Eptif-d~liele caused a concentration dependent effect on Re 
that mirrored tt~ olosen~cl inhibition of PA. Re has advantages in that 8 
pre~lrug sample is net mquirecl and assessment can be corned Out up to 72 
hm post blo~cl collection. Re is an excellent altemat~e method far r~onlt0nng 
receptor blockade. 
[ 1028.1101 Dose Ranging Study of Intravenous RPR 109891 
.... in Patients Wdh Acute Coronary Syndromes - 
Results of  TIM115A 
R.P. Giugliano, C.H. McCabe, fl.F. Sequeira, TO. Henry, R.N. Pians, 
MJ. Schweiger, H.S. Mustier, S. Borzak, M.D. l"ischlor, J.-F. Tamby, 
K.E. Ramsay, MV, Jacaski, R.J, Wise, E. Braunwald. Brigham and 
Women's Hospital, Boston, MA, USA 
Platelet glycOpmteth Ilbillla receptor blockade is beneficial in bigh-nsk un- 
stable angina and angiop;asty. RPR 109891 is a unique competitive inhibitor 
because it is available in both IV and oral formulations, To stucly the dose 
response of the IV formulation, TIM115A is randomizing patients with acute 
coronary swdmmes to receive IV RPR 109891 for 24-96 hours. The primary 
endpolnt is inhibition of ptatelot aggregation 0PA) using ADP-20 pM Mean 
IPA at 20 minutes, pro-stop and 2-4 hfs post stop am shown below for 5 
ton" 60/0.8 (n=t3) 
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